Zum Inhalt springen

Achtung: Bitte beachten Sie unbedingt die Nutzungsbedingungen. Trotz sorgfältiger Prüfung wird keinerlei Haftung für die dargestellten Inhalte übernommen. Alle Inhalte richten sich ausschließlich an ein ärztliches Fachpublikum.

DGI:Opportunistische Infektionen/Kryptokokkose/Quellen: Unterschied zwischen den Versionen

Aus Infektiopedia
← Zum vorherigen Versionsunterschied
Bestem (Diskussion | Beiträge)
Ambulant erworbene Pneumonie, Kapitel 3, Zentralredaktion, editor, Administratoren
4.485 Bearbeitungen
Keine Bearbeitungszusammenfassung
Kristina.jozic (Diskussion | Beiträge)
Zentralredaktion, editor, reviewer, Administratoren
343 Bearbeitungen
Keine Bearbeitungszusammenfassung
 
(2 dazwischenliegende Versionen desselben Benutzers werden nicht angezeigt)
Zeile 1: Zeile 1:
*Pappas PG. Cryptococcal infections in non-HIV-infected patients. Trans Am Clin Climatol Assoc. 2013;124:61-79.
 
*Negroni R. Cryptococcosis. Clin Dermatol. 2012;30(6):599-609.
*Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. . Available at <nowiki>http://aidsinfonihgov/contentfiles/lvguidelines/adult_oipdf</nowiki>  Accessed on 02 02 2020W1-W18
*Kluger N, Poirier P, Guilpain P, Baixench MT, Cohen P, Paugam A. Cryptococcal meningitis in a patient treated with infliximab and mycophenolate mofetil for Behcet's disease. Int J Infect Dis. 2009;13(5):e325.
*Iwata T, Nagano T, Tomita M, et al. Adalimumab-associated pulmonary cryptococcosis. Ann Thorac Cardiovasc Surg. 2011;17(4):390-393.
*Ingram PR, Howman R, Leahy MF, Dyer JR. Cryptococcal immune reconstitution inflammatory syndrome following alemtuzumab therapy. Clin Infect Dis. 2007;44(12):e115-117.
*Messina JA, Maziarz EK, Spec A, Kontoyiannis DP, Perfect JR. Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib. Open Forum Infect Dis. 2017;4(1):ofw261.
*Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS. 2009;23(4):525-530.
*Chen J, Zhang R, Shen Y, et al. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis. HIV Med. 2019;20(1):69-73.
*Pongmekin P, Chongtrakool P, Santanirand P, Kiertiburanakul S. Clinical characteristics and mortality risk factors of cryptococcal infection among HIV-negative patients. J Med Assoc Thai. 2014;97(1):36-43.
*Jean SS, Fang CT, Shau WY, et al. Cryptococcaemia: clinical features and prognostic factors. QJM. 2002;95(8):511-518.
*Sajadi MM, Roddy KM, Chan-Tack KM, Forrest GN. Risk factors for mortality from primary cryptococcosis in patients with HIV. Postgrad Med. 2009;121(2):107-113.
*Shaunak S, Schell WA, Perfect JR. Cryptococcal meningitis with normal cerebrospinal fluid. J Infect Dis. 1989;160(5):912.
*Ford N, Shubber Z, Jarvis JN, et al. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis. Clin Infect Dis. 2018;66(suppl_2):S152-S159.
*Nelson M, Dockrell D, Edwards S, et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Med. 2011;12 Suppl 2:1-140.
*Tan IL, Smith BR, von Geldern G, Mateen FJ, McArthur JC. HIV-associated opportunistic infections of the CNS. Lancet Neurol. 2012;11(7):605-617.
*Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291-322.
*Byrnes EJ, 3rd, Bartlett KH, Perfect JR, Heitman J. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect. 2011;13(11):895-907.
*Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis. 2000;30(1):47-54.
*In: Guidelines for The Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children: Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Geneva2018.
*European Guidelines for the treatment of HIV-positive adults in Europe. 2019. <nowiki>https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf.(10.0)</nowiki>.
*European Guidelines for the treatment of HIV-positive adults in Europe. 2019. <nowiki>https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf.(10.0)</nowiki>.
*Shelburne SA, 3rd, Darcourt J, White AC, Jr., et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(7):1049-1052.
*Shelburne SA, 3rd, Darcourt J, White AC, Jr., et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(7):1049-1052.
*Govender NP, Meintjes G, Mangena P, et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. South Afr J HIV Med. 2019;20(1):1030.
*Govender NP, Meintjes G, Mangena P, et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. South Afr J HIV Med. 2019;20(1):1030.
*Spec A, Mejia-Chew C, Powderly WG, Cornely OA. EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management. Open Forum Infect Dis. 2018;5(11):ofy299.
*Spec A, Mejia-Chew C, Powderly WG, Cornely OA. EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management. Open Forum Infect Dis. 2018;5(11):ofy299.

Aktuelle Version vom 15. Oktober 2026, 09:41 Uhr

  • European Guidelines for the treatment of HIV-positive adults in Europe. 2019. https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf.(10.0).
  • Shelburne SA, 3rd, Darcourt J, White AC, Jr., et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40(7):1049-1052.
  • Govender NP, Meintjes G, Mangena P, et al. Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update. South Afr J HIV Med. 2019;20(1):1030.
  • Spec A, Mejia-Chew C, Powderly WG, Cornely OA. EQUAL Cryptococcus Score 2018: A European Confederation of Medical Mycology Score Derived From Current Guidelines to Measure QUALity of Clinical Cryptococcosis Management. Open Forum Infect Dis. 2018;5(11):ofy299.

Humanes Immundefizienz-Virus

Acquired immunodeficiency syndrome (engl.), erworbenes Immunschwächesyndrom, auch Akquiriertes Immun-Defizienz-Syndrom; siehe auch Kapitel Nosokomiale Pneumonie

Abgerufen von „https://infektiopedia.de/w/index.php?title=DGI:Opportunistische_Infektionen/Kryptokokkose/Quellen&oldid=10624“